A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure☆
Section snippets
Methods
The methods used in the 6-month comparison trial of bimatoprost and latanoprost were described in detail previously16 and are briefly summarized here.
Patient disposition and characteristics
A full description of the patient population has been published previously.16 In summary, of 320 patients who were screened, 51 (19%) did not meet the inclusion/exclusion criteria, and 269 were enrolled (n = 133 bimatoprost and n = 136 latanoprost). A total of 249 patients (92.6%) completed the study (bimatoprost, n = 124; latanoprost, n = 125). Patients ranged in age from 24–88 (mean 61.3) years and nearly two-thirds were women. Most patients were white (83%; 223/269), while 11% (29/269) were black
Discussion
This analysis of diurnal responder rates found that a significantly greater proportion of patients treated with bimatoprost than with latanoprost consistently showed a substantial, clinically relevant lowering of IOP, defined as a decrease of at least 15% or 20% from baseline throughout the day.
Diurnal responder rates may provide important, clinically relevant information about the clinical utility of a drug because studies have suggested that it is important to maintain consistent IOP control
Conclusion
This post hoc analysis of data from our previously published study offers further evidence that bimatoprost provides superior IOP control to latanoprost. Although the selection of any medication will, of course, take individual patient factors into account, results from such analyses may assist in guiding clinical practice by providing a strong evidence base for medication selection.
Method of literature search
A search of the Medline database was used to identify relevant papers published from 1990 through 2003. The search terms used were: latanoprost, bimatoprost, responder, glaucoma, and diurnal IOP. The most relevant references are cited in this article.
References (24)
- et al.
A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension
Am J Ophthalmol
(2001) - et al.
Impact of intraocular pressure regulation on visual fields in open-angle glaucoma
Ophthalmology
(1999) - et al.
Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups
Ophthalmology
(1996) - et al.
Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost
Surv Ophthalmol
(2001) - et al.
Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost
Ophthalmology
(2003) - et al.
The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients
Surv Ophthalmol
(2002) - et al.
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
Am J Ophthalmol
(2003) - et al.
A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data
Am J Ophthalmol
(2002) - et al.
Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision
Am J Ophthalmol
(2002) - et al.
A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study
Am J Ophthalmol
(2003)
Factors associated with long-term progression or stability in primary open-angle glaucoma
Am J Ophthalmol
7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators
Am J Ophthalmol
Cited by (0)
- ☆
This study was sponsored by Allergan Inc. Paula Bernstein, MS, Scott Whitcup, MD, and Amy Batoosingh, BA, are employees of Allergan Inc.